What makes health systems resilient against infectious disease outbreaks and natural hazards? Results from a scoping review
The 2014 –2016 Ebola outbreak was a wake-up call regarding the critical importance of resilient health systems. Fragile health systems can become overwhelmed during public health crises, further exacerbating th...
Congo’s president hopes deadly Ebola outbreak will end in the coming weeks
An outbreak of Ebola in eastern Democratic Republic of Congo should be eradicated by the end of 2019, Congolese President Felix Tshisekedi said on Friday.
[Deutsche Welle] Authorities in the Democratic Republic of Congo have started using a second vaccine to fight Ebola. The country is struggling to contain what is now the world's second-worst outbreak of the deadly virus on record.
This study provides a better understanding of GP expression and processing in BmN cells, which may lay a foundation for EBOV-GP expression using the BmNPV baculovirus expression system.
Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson&Johnson, aid group MSF said on Thursday, to help combat the world's second-worst outbreak of the virus on record.
Six new confirmed cases were reported in the past week (6 to 12 November) in the ongoing Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces.
An eight-month-old boy is examined by a doctor in Dar es Salaam, Tanzania. Credit: Kristin Palitza/IPS By Ifeanyi NsoforABUJA, Nov 7 2019 (IPS) Free movement of people and goods across Africa increases the risk of transmission of infectious diseases. The continent must realise that it is no longer a question of if disease outbreaks will occur, but instead, of when, and how fast. The U.S. Centres for Disease Control says that within 36 hours, a disease outbreak can spread from a remote village to major urban cities of the world. According to preventepidemics.org, a website which ranks countries’ levels of e...
Fifteen confirmed cases were reported in the past week (30 October – 5 November) in the ongoing Ebola virus disease (EVD) outbreak in North Kivu and Ituri provinces
Authors: Villanueva J, Schweitzer B, Odle M, Aden T Abstract The Laboratory Response Network (LRN) was established in 1999 to ensure an effective laboratory response to high-priority public health threats. The LRN for biological threats (LRN-B) provides a laboratory infrastructure to respond to emerging infectious diseases. Since 2012, the LRN-B has been involved in 3 emerging infectious disease outbreak responses. We evaluated the LRN-B role in these responses and identified areas for improvement. LRN-B laboratories tested 1097 specimens during the 2014 Middle East Respiratory Syndrome Coronavirus outbreak, 180 sp...
This study found demonstrable induction of the inflammatory response, and increase in the activation state of THP-1 macrophages infected with Makona. NFκB and inflammation-associated transcripts displayed significant changes in abundance, reflective of what was observed in human patients during the 2013–2016 EBOV outbreak in West Africa, and demonstrated that transcriptomic changes found in Makona-infected cells were similar to that observed in Reston virus infection and that have been described in previous studies of other variants of EBOV.